Richard Schlegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Richard Schlegel has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Xuefeng Liu
The Ohio State University
6 shared publications Aleksandra Dakic
Department of Pathology, Georgetown University Medical School, Washington DC, 20057, USA
3 shared publications- Ewa Krawczyk
Georgetown University Medical Center
3 shared publications - Hang Yuan
Department of Pathology, Georgetown University Medical School, Washington, DC 20057, USA
3 shared publications Nancy Palechor-Ceron
Department of Pathology, Georgetown University Medical School, Washington DC, 20057, USA
3 shared publicationsChristopher Albanese
Department of Pathology, Georgetown University Medical School, Washington DC, 20057, USA
2 shared publications
Latest Publications
- Open Access
- 6 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26  (9) , 4391
A Universal and Quantitative PCR Strategy for Detection and Epidemiologic Analysis of Canine Papillomavirus (CPV)
Canine papillomavirus (CPV) infection leads to a range of clinical manifestations from benign warts to malignant tumors in dogs, posing significant challenges in veterinary medicine due to its diverse genotypic spectrum. This study introduced broad-range and robust polymerase chain reaction (PCR) assays designed to enhance the detection, identification, and quantification of multiple CPV genotypes. By using both universal and genotype-specific primers, this protocol significantly improved diagnostic specificity and sensitivity across the 23 known CPV genotypes compared to previously described ones. The primers were designed to target conserved regions across all genotypes for general detection, as well as specific regions in the predominant genotypes CPV1 and CPV2 for detailed analysis. Validation of this protocol using synthetic plasmids and clinical samples confirmed its enhanced performance over traditional methods, as demonstrated by higher specificity and sensitivity. Additionally, the application of this PCR approach in a series of epidemiological studies provided novel insights into the distribution and prevalence of CPV genotypes, highlighting its potential utility in shaping targeted vaccination and clinical management strategies. Furthermore, the quantitative capability of this established protocol allowed for monitoring viral loads in clinical cases, offering a valuable tool for assessing treatment efficacy and disease progression. Further validation through larger-scale clinical studies will be crucial to substantiate the diagnostic accuracy and epidemiological value of the assays.
- 6 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26  (9) , 4391
Open AccessA Universal and Quantitative PCR Strategy for Detection and Epidemiologic Analysis of Canine Papillomavirus (CPV)
Canine papillomavirus (CPV) infection leads to a range of clinical manifestations from benign warts to malignant tumors in dogs, posing significant challenges in veterinary medicine due to its diverse genotypic spectrum. This study introduced broad-range and robust polymerase chain reaction (PCR) assays designed to enhance the detection, identification, and quantification of multiple CPV genotypes. By using both universal and genotype-specific primers, this protocol significantly improved diagnostic specificity and sensitivity across the 23 known CPV genotypes compared to previously described ones. The primers were designed to target conserved regions across all genotypes for general detection, as well as specific regions in the predominant genotypes CPV1 and CPV2 for detailed analysis. Validation of this protocol using synthetic plasmids and clinical samples confirmed its enhanced performance over traditional methods, as demonstrated by higher specificity and sensitivity. Additionally, the application of this PCR approach in a series of epidemiological studies provided novel insights into the distribution and prevalence of CPV genotypes, highlighting its potential utility in shaping targeted vaccination and clinical management strategies. Furthermore, the quantitative capability of this established protocol allowed for monitoring viral loads in clinical cases, offering a valuable tool for assessing treatment efficacy and disease progression. Further validation through larger-scale clinical studies will be crucial to substantiate the diagnostic accuracy and epidemiological value of the assays.
- Open Access
Unlocking Translational Potential: Conditionally Reprogrammed Cells in Advancing Breast Cancer Research
Preclinical in vitro models play an important role in studying cancer cell biology and facilitating translational research, especially in the identification of drug targets and drug discovery studies. This is particularly relevant in breast cancer, where the global burden of disease is quite high based on prevalence and a relatively high rate of lethality. Predictive tools to select patients who will be responsive to invasive or morbid therapies (radiotherapy, chemotherapy, immunotherapy, and/or surgery) are relatively lacking. To be clinically relevant, a model must accurately replicate the biology and cellular heterogeneity of the primary tumor. Addressing these requirements and overcoming the limitations of most existing cancer cell lines, which are typically derived from a single clone, we have recently developed conditional reprogramming (CR) technology. The CR technology refers to a co-culture system of primary human normal or tumor cells with irradiated murine fibroblasts in the presence of a Rho-associated kinase inhibitor to allow the primary cells to acquire stem cell properties and the ability to proliferate indefinitely in vitro without any exogenous gene or viral transfection. This innovative approach fulfills many of these needs and offers an alternative that surpasses the deficiencies associated with traditional cancer cell lines. These CR cells (CRCs) can be reprogrammed to maintain a highly proliferative state and reproduce the genomic and histological characteristics of the parental tissue. Therefore, CR technology may be a clinically relevant model to test and predict drug sensitivity, conduct gene profile analysis and xenograft research, and undertake personalized medicine. This review discusses studies that have applied CR technology to conduct breast cancer research.
Open AccessUnlocking Translational Potential: Conditionally Reprogrammed Cells in Advancing Breast Cancer Research
Preclinical in vitro models play an important role in studying cancer cell biology and facilitating translational research, especially in the identification of drug targets and drug discovery studies. This is particularly relevant in breast cancer, where the global burden of disease is quite high based on prevalence and a relatively high rate of lethality. Predictive tools to select patients who will be responsive to invasive or morbid therapies (radiotherapy, chemotherapy, immunotherapy, and/or surgery) are relatively lacking. To be clinically relevant, a model must accurately replicate the biology and cellular heterogeneity of the primary tumor. Addressing these requirements and overcoming the limitations of most existing cancer cell lines, which are typically derived from a single clone, we have recently developed conditional reprogramming (CR) technology. The CR technology refers to a co-culture system of primary human normal or tumor cells with irradiated murine fibroblasts in the presence of a Rho-associated kinase inhibitor to allow the primary cells to acquire stem cell properties and the ability to proliferate indefinitely in vitro without any exogenous gene or viral transfection. This innovative approach fulfills many of these needs and offers an alternative that surpasses the deficiencies associated with traditional cancer cell lines. These CR cells (CRCs) can be reprogrammed to maintain a highly proliferative state and reproduce the genomic and histological characteristics of the parental tissue. Therefore, CR technology may be a clinically relevant model to test and predict drug sensitivity, conduct gene profile analysis and xenograft research, and undertake personalized medicine. This review discusses studies that have applied CR technology to conduct breast cancer research.
- Open Access
Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis
Circulating tumor cells (CTCs) represent a unique population of cells that can be used to investigate the mechanistic underpinnings of metastasis. Unfortunately, current technologies designed for the isolation and capture of CTCs are inefficient. Existing literature for in vitro CTC cultures report low (6−20%) success rates. Here, we describe a new method for the isolation and culture of CTCs. Once optimized, we employed the method on 12 individual metastatic breast cancer patients and successfully established CTC cultures from all 12 samples. We demonstrate that cells propagated were of breast and epithelial origin. RNA-sequencing and pathway analysis demonstrated that CTC cultures were distinct from cells obtained from healthy donors. Finally, we observed that CTC cultures that were associated with CD45+ leukocytes demonstrated higher viability. The presence of CD45+ leukocytes significantly enhanced culture survival and suggests a re-evaluation of the methods for CTC isolation and propagation. Routine access to CTCs is a valuable resource for identifying genetic and molecular markers of metastasis, personalizing the treatment of metastatic cancer patients and developing new therapeutics to selectively target metastatic cells.
Open AccessEfficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis
Circulating tumor cells (CTCs) represent a unique population of cells that can be used to investigate the mechanistic underpinnings of metastasis. Unfortunately, current technologies designed for the isolation and capture of CTCs are inefficient. Existing literature for in vitro CTC cultures report low (6−20%) success rates. Here, we describe a new method for the isolation and culture of CTCs. Once optimized, we employed the method on 12 individual metastatic breast cancer patients and successfully established CTC cultures from all 12 samples. We demonstrate that cells propagated were of breast and epithelial origin. RNA-sequencing and pathway analysis demonstrated that CTC cultures were distinct from cells obtained from healthy donors. Finally, we observed that CTC cultures that were associated with CD45+ leukocytes demonstrated higher viability. The presence of CD45+ leukocytes significantly enhanced culture survival and suggests a re-evaluation of the methods for CTC isolation and propagation. Routine access to CTCs is a valuable resource for identifying genetic and molecular markers of metastasis, personalizing the treatment of metastatic cancer patients and developing new therapeutics to selectively target metastatic cells.
- Open Access
Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Traditional cancer models including cell lines and animal models have limited applications in both basic and clinical cancer research. Genomics-based precision oncology only help 2–20% patients with solid cancer. Functional diagnostics and patient-derived cancer models are needed for precision cancer biology. In this review, we will summarize applications of conditional cell reprogramming (CR) in cancer research and next generation living biobanks (NGLB). Together with organoids, CR has been cited in two NCI (National Cancer Institute, USA) programs (PDMR: patient-derived cancer model repository; HCMI: human cancer model initiatives. HCMI will be distributed through ATCC). Briefly, the CR method is a simple co-culture technology with a Rho kinase inhibitor, Y-27632, in combination with fibroblast feeder cells, which allows us to rapidly expand both normal and malignant epithelial cells from diverse anatomic sites and mammalian species and does not require transfection with exogenous viral or cellular genes. Establishment of CR cells from both normal and tumor tissue is highly efficient. The robust nature of the technique is exemplified by the ability to produce 2 × 106 cells in five days from a core biopsy of tumor tissue. Normal CR cell cultures retain a normal karyotype and differentiation potential and CR cells derived from tumors retain their tumorigenic phenotype. CR also allows us to enrich cancer cells from urine (for bladder cancer), blood (for prostate cancer), and pleural effusion (for non-small cell lung carcinoma). The ability to produce inexhaustible cell populations using CR technology from small biopsies and cryopreserved specimens has the potential to transform biobanking repositories (NGLB: next-generation living biobank) and current pathology practice by enabling genetic, biochemical, metabolomic, proteomic, and biological assays, including chemosensitivity testing as a functional diagnostics tool for precision cancer medicine. We discussed analyses of patient-derived matched normal and tumor models using a case with tongue squamous cell carcinoma as an example. Last, we summarized applications in cancer research, disease modeling, drug discovery, and regenerative medicine of CR-based NGLB.
Open AccessConditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Traditional cancer models including cell lines and animal models have limited applications in both basic and clinical cancer research. Genomics-based precision oncology only help 2–20% patients with solid cancer. Functional diagnostics and patient-derived cancer models are needed for precision cancer biology. In this review, we will summarize applications of conditional cell reprogramming (CR) in cancer research and next generation living biobanks (NGLB). Together with organoids, CR has been cited in two NCI (National Cancer Institute, USA) programs (PDMR: patient-derived cancer model repository; HCMI: human cancer model initiatives. HCMI will be distributed through ATCC). Briefly, the CR method is a simple co-culture technology with a Rho kinase inhibitor, Y-27632, in combination with fibroblast feeder cells, which allows us to rapidly expand both normal and malignant epithelial cells from diverse anatomic sites and mammalian species and does not require transfection with exogenous viral or cellular genes. Establishment of CR cells from both normal and tumor tissue is highly efficient. The robust nature of the technique is exemplified by the ability to produce 2 × 106 cells in five days from a core biopsy of tumor tissue. Normal CR cell cultures retain a normal karyotype and differentiation potential and CR cells derived from tumors retain their tumorigenic phenotype. CR also allows us to enrich cancer cells from urine (for bladder cancer), blood (for prostate cancer), and pleural effusion (for non-small cell lung carcinoma). The ability to produce inexhaustible cell populations using CR technology from small biopsies and cryopreserved specimens has the potential to transform biobanking repositories (NGLB: next-generation living biobank) and current pathology practice by enabling genetic, biochemical, metabolomic, proteomic, and biological assays, including chemosensitivity testing as a functional diagnostics tool for precision cancer medicine. We discussed analyses of patient-derived matched normal and tumor models using a case with tongue squamous cell carcinoma as an example. Last, we summarized applications in cancer research, disease modeling, drug discovery, and regenerative medicine of CR-based NGLB.
- Open Access
- 4 July 2018
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 9  (1) , 181
Long-term expansion of primary equine keratinocytes that maintain the ability to differentiate into stratified epidermis
Skin injuries in horses frequently lead to chronic wounds that lack a keratinocyte cover essential for healing. The limited proliferation of equine keratinocytes using current protocols has limited their use for regenerative medicine. Previously, equine induced pluripotent stem cells (eiPSCs) have been produced, and eiPSCs could be differentiated into equine keratinocytes suitable for stem cell-based skin constructs. However, the procedure is technically challenging and time-consuming. The present study was designed to evaluate whether conditional reprogramming (CR) could expand primary equine keratinocytes rapidly in an undifferentiated state but retain their ability to differentiate normally and form stratified epithelium. Conditional reprogramming was used to isolate and propagate two equine keratinocyte cultures. PCR and FISH were employed to evaluate the equine origin of the cells and karyotyping to perform a chromosomal count. FACS analysis and immunofluorescence were used to determine the purity of equine keratinocytes and their proliferative state. Three-dimensional air-liquid interphase method was used to test the ability of cells to differentiate and form stratified squamous epithelium. Conditional reprogramming was an efficient method to isolate and propagate two equine keratinocyte cultures. Cells were propagated at the rate of 2.39 days/doubling for more than 40 population doublings. A feeder-free culture method was also developed for long-term expansion. Rock-inhibitor is critical for both feeder and feeder-free conditions and for maintaining the proliferating cells in a stem-like state. PCR and FISH validated equine-specific markers in the cultures. Karyotyping showed normal equine 64, XY chromosomes. FACS using pan-cytokeratin antibodies showed a pure population of keratinocytes. When ROCK inhibitor was withdrawn and the cells were transferred to a three-dimensional air-liquid culture, they formed a well-differentiated stratified squamous epithelium, which was positive for terminal differentiation markers. Our results prove that conditional reprogramming is the first method that allows for the rapid and continued in vitro propagation of primary equine keratinocytes. These unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection. This offers the opportunity for treating recalcitrant horse wounds using autologous transplantation.
- 4 July 2018
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 9  (1) , 181
Open AccessLong-term expansion of primary equine keratinocytes that maintain the ability to differentiate into stratified epidermis
Skin injuries in horses frequently lead to chronic wounds that lack a keratinocyte cover essential for healing. The limited proliferation of equine keratinocytes using current protocols has limited their use for regenerative medicine. Previously, equine induced pluripotent stem cells (eiPSCs) have been produced, and eiPSCs could be differentiated into equine keratinocytes suitable for stem cell-based skin constructs. However, the procedure is technically challenging and time-consuming. The present study was designed to evaluate whether conditional reprogramming (CR) could expand primary equine keratinocytes rapidly in an undifferentiated state but retain their ability to differentiate normally and form stratified epithelium. Conditional reprogramming was used to isolate and propagate two equine keratinocyte cultures. PCR and FISH were employed to evaluate the equine origin of the cells and karyotyping to perform a chromosomal count. FACS analysis and immunofluorescence were used to determine the purity of equine keratinocytes and their proliferative state. Three-dimensional air-liquid interphase method was used to test the ability of cells to differentiate and form stratified squamous epithelium. Conditional reprogramming was an efficient method to isolate and propagate two equine keratinocyte cultures. Cells were propagated at the rate of 2.39 days/doubling for more than 40 population doublings. A feeder-free culture method was also developed for long-term expansion. Rock-inhibitor is critical for both feeder and feeder-free conditions and for maintaining the proliferating cells in a stem-like state. PCR and FISH validated equine-specific markers in the cultures. Karyotyping showed normal equine 64, XY chromosomes. FACS using pan-cytokeratin antibodies showed a pure population of keratinocytes. When ROCK inhibitor was withdrawn and the cells were transferred to a three-dimensional air-liquid culture, they formed a well-differentiated stratified squamous epithelium, which was positive for terminal differentiation markers. Our results prove that conditional reprogramming is the first method that allows for the rapid and continued in vitro propagation of primary equine keratinocytes. These unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection. This offers the opportunity for treating recalcitrant horse wounds using autologous transplantation.
- Open Access
- 5 April 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , srep45617
HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes
Using conditional cell reprogramming, we generated a stable cell culture of an extremely rare and aggressive neuroendocrine cervical cancer. The cultured cells contained HPV-16, formed colonies in soft agar and rapidly produced tumors in immunodeficient mice. The HPV-16 genome was integrated adjacent to the Myc gene, both of which were amplified 40-fold. Analysis of RNA transcripts detected fusion of the HPV/Myc genes, arising from apparent microhomologous recombination. Spectral karyotyping (SKY) and fluorescent-in-situ hybridization (FISH) demonstrated coordinate localization and translocation of the amplified Myc and HPV genes on chromosomes 8 and 21. Similar to the primary tumor, tumor cell cultures expressed very high levels of the Myc protein and, in contrast to all other HPV-positive cervical cancer cell lines, they harbored a gain-of-function mutation in p53 (R273C). Unexpectedly, viral oncogene knockdown had no effect on the growth of the cells, but it did inhibit the proliferation of a conventional HPV-16 positive cervical cancer cell line. Knockdown of Myc, but not the mutant p53, significantly inhibited tumor cell proliferation. On the basis of these data, we propose that the primary driver of transformation in this aggressive cervical cancer is not HPV oncogene expression but rather the overexpression of Myc.
- 5 April 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , srep45617
Open AccessHPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes
Using conditional cell reprogramming, we generated a stable cell culture of an extremely rare and aggressive neuroendocrine cervical cancer. The cultured cells contained HPV-16, formed colonies in soft agar and rapidly produced tumors in immunodeficient mice. The HPV-16 genome was integrated adjacent to the Myc gene, both of which were amplified 40-fold. Analysis of RNA transcripts detected fusion of the HPV/Myc genes, arising from apparent microhomologous recombination. Spectral karyotyping (SKY) and fluorescent-in-situ hybridization (FISH) demonstrated coordinate localization and translocation of the amplified Myc and HPV genes on chromosomes 8 and 21. Similar to the primary tumor, tumor cell cultures expressed very high levels of the Myc protein and, in contrast to all other HPV-positive cervical cancer cell lines, they harbored a gain-of-function mutation in p53 (R273C). Unexpectedly, viral oncogene knockdown had no effect on the growth of the cells, but it did inhibit the proliferation of a conventional HPV-16 positive cervical cancer cell line. Knockdown of Myc, but not the mutant p53, significantly inhibited tumor cell proliferation. On the basis of these data, we propose that the primary driver of transformation in this aggressive cervical cancer is not HPV oncogene expression but rather the overexpression of Myc.
- Top Cited Papers
- 26 January 2017
- Published by Springer Nature in Nature Protocols
- Vol. 12  (2) , 439-451
Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens
This protocol demonstrates how to establish primary epithelial cell cultures in vitro from healthy human tissue and human cancer samples using ROCK inhibitor and irradiated feeder cells. Historically, it has been difficult to propagate cells in vitro that are derived directly from human tumors or healthy tissue. However, in vitro preclinical models are essential tools for both the study of basic cancer biology and the promotion of translational research, including drug discovery and drug target identification. This protocol describes conditional reprogramming (CR), which involves coculture of irradiated mouse fibroblast feeder cells with normal and tumor human epithelial cells in the presence of a Rho kinase inhibitor (Y-27632). CR cells can be used for various applications, including regenerative medicine, drug sensitivity testing, gene expression profiling and xenograft studies. The method requires a pathologist to differentiate healthy tissue from tumor tissue, and basic tissue culture skills. The protocol can be used with cells derived from both fresh and cryopreserved tissue samples. As approximately 1 million cells can be generated in 7 d, the technique is directly applicable to diagnostic and predictive medicine. Moreover, the epithelial cells can be propagated indefinitely in vitro, yet retain the capacity to become fully differentiated when placed into conditions that mimic their natural environment.
- 26 January 2017
- Published by Springer Nature in Nature Protocols
- Vol. 12  (2) , 439-451
Top Cited PapersConditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens
This protocol demonstrates how to establish primary epithelial cell cultures in vitro from healthy human tissue and human cancer samples using ROCK inhibitor and irradiated feeder cells. Historically, it has been difficult to propagate cells in vitro that are derived directly from human tumors or healthy tissue. However, in vitro preclinical models are essential tools for both the study of basic cancer biology and the promotion of translational research, including drug discovery and drug target identification. This protocol describes conditional reprogramming (CR), which involves coculture of irradiated mouse fibroblast feeder cells with normal and tumor human epithelial cells in the presence of a Rho kinase inhibitor (Y-27632). CR cells can be used for various applications, including regenerative medicine, drug sensitivity testing, gene expression profiling and xenograft studies. The method requires a pathologist to differentiate healthy tissue from tumor tissue, and basic tissue culture skills. The protocol can be used with cells derived from both fresh and cryopreserved tissue samples. As approximately 1 million cells can be generated in 7 d, the technique is directly applicable to diagnostic and predictive medicine. Moreover, the epithelial cells can be propagated indefinitely in vitro, yet retain the capacity to become fully differentiated when placed into conditions that mimic their natural environment.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , e23188
Patient-derived cell models for cancer precision medicine.
E23188 Background: Recently, we described the conditional reprogramming (CR) which allows to rapidly establish primary cultures from normal and tumor specimens. The Combination of CR and Organoids ( (Matrigel, air-liquid interface (ALI)) cultures represents next generation human cancer models and functional diagnostics for cancer precision medicine as described in August in the NCI precision medicine initiative and three nature review articles (Nat Rev Cancer. 2015 Dec; Nat Rev Genet. 2015 Jul; Nat Rev Clin Oncol. 2014 Nov.). The technique is relatively simple and has been reproduced in more than 50 laboratories (including an original and independent article in Science from Massachusetts General Hospital) (Science. 2014, 346(6216):1480-6.). Importantly, the CR technology can generate 2×106cells in a week from small biopsies, and can generate cultures from cryopreserved tissue and from fewer than four viable cells. We therefore initiated studies to examine whether CR cultures reflected the biology and genotype of the original tumor and whether cultures might be used to predict clinical responses. Methods: Surgical specimens from patients with prostate and lung cancer were collected. CR and Organoids cultures were used. Results: We first worked out standard protocols for clinical sampling, storage, shipping, freezing and the preparation of conditioned medium. CR methods were then used to generate matched cultures from both tumor cells and adjacent normal cells from patients with prostate cancer or lung cancer. CR cultures were established efficiently from these tumors ( > 95% for prostate and lung cancer CRCs). The data with Organoids cultures demonstrated that CR cells re-expressed cell specific markers and were well-differentiated. We also characterized them for their growth properties, induction of tumors in immunodeficient mice, karyotype, and their exome and transcriptome profile. Conclusions: The combination of CR (2D) and Organoids (3D) culture conditions provides optimal conditions for establishing patient-derived cells and for study of translational cancer biology. These cell-based approaches should be useful for defining the functional heterogeneity of the respective primary tumors and for evaluating appropriate therapies.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , e23188
Patient-derived cell models for cancer precision medicine.
E23188 Background: Recently, we described the conditional reprogramming (CR) which allows to rapidly establish primary cultures from normal and tumor specimens. The Combination of CR and Organoids ( (Matrigel, air-liquid interface (ALI)) cultures represents next generation human cancer models and functional diagnostics for cancer precision medicine as described in August in the NCI precision medicine initiative and three nature review articles (Nat Rev Cancer. 2015 Dec; Nat Rev Genet. 2015 Jul; Nat Rev Clin Oncol. 2014 Nov.). The technique is relatively simple and has been reproduced in more than 50 laboratories (including an original and independent article in Science from Massachusetts General Hospital) (Science. 2014, 346(6216):1480-6.). Importantly, the CR technology can generate 2×106cells in a week from small biopsies, and can generate cultures from cryopreserved tissue and from fewer than four viable cells. We therefore initiated studies to examine whether CR cultures reflected the biology and genotype of the original tumor and whether cultures might be used to predict clinical responses. Methods: Surgical specimens from patients with prostate and lung cancer were collected. CR and Organoids cultures were used. Results: We first worked out standard protocols for clinical sampling, storage, shipping, freezing and the preparation of conditioned medium. CR methods were then used to generate matched cultures from both tumor cells and adjacent normal cells from patients with prostate cancer or lung cancer. CR cultures were established efficiently from these tumors ( > 95% for prostate and lung cancer CRCs). The data with Organoids cultures demonstrated that CR cells re-expressed cell specific markers and were well-differentiated. We also characterized them for their growth properties, induction of tumors in immunodeficient mice, karyotype, and their exome and transcriptome profile. Conclusions: The combination of CR (2D) and Organoids (3D) culture conditions provides optimal conditions for establishing patient-derived cells and for study of translational cancer biology. These cell-based approaches should be useful for defining the functional heterogeneity of the respective primary tumors and for evaluating appropriate therapies.